Heron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report) saw some unusual options trading on Tuesday. Stock investors acquired 11,901 call options on the stock. This is an increase of approximately 1,867% compared to the average daily volume of 605 call options.
Heron Therapeutics Trading Up 0.9 %
Shares of NASDAQ:HRTX traded up $0.02 during midday trading on Friday, hitting $2.19. The stock had a trading volume of 386,212 shares, compared to its average volume of 2,311,244. Heron Therapeutics has a 1 year low of $1.04 and a 1 year high of $3.93. The stock has a 50 day moving average price of $2.19 and a two-hundred day moving average price of $1.82. The company has a market capitalization of $334.04 million, a PE ratio of -12.17 and a beta of 1.33.
Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 EPS for the quarter, topping analysts' consensus estimates of ($0.01) by $0.02. The firm had revenue of $38.90 million during the quarter, compared to analyst estimates of $37.08 million. As a group, equities analysts expect that Heron Therapeutics will post -0.13 EPS for the current year.
Institutional Investors Weigh In On Heron Therapeutics
Several large investors have recently made changes to their positions in the stock. Nicolet Advisory Services LLC bought a new position in Heron Therapeutics in the fourth quarter worth approximately $25,000. RFP Financial Group LLC bought a new stake in shares of Heron Therapeutics during the first quarter valued at about $26,000. Argent Advisors Inc. purchased a new position in shares of Heron Therapeutics during the 4th quarter valued at about $31,000. Focus Partners Wealth purchased a new stake in Heron Therapeutics during the fourth quarter valued at about $31,000. Finally, Valeo Financial Advisors LLC boosted its position in Heron Therapeutics by 34.1% during the 1st quarter. Valeo Financial Advisors LLC now owns 18,152 shares of the biotechnology company's stock valued at $40,000 after buying an additional 4,619 shares during the period. Institutional investors and hedge funds own 80.01% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts have recently weighed in on the company. StockNews.com lowered Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, March 8th. Needham & Company LLC reaffirmed a "buy" rating and set a $4.00 target price on shares of Heron Therapeutics in a research note on Friday, April 11th.
Read Our Latest Research Report on HRTX
About Heron Therapeutics
(
Get Free Report)
Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Featured Stories
Before you consider Heron Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Heron Therapeutics wasn't on the list.
While Heron Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
